KR102132144B1 - 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 - Google Patents

폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 Download PDF

Info

Publication number
KR102132144B1
KR102132144B1 KR1020207003791A KR20207003791A KR102132144B1 KR 102132144 B1 KR102132144 B1 KR 102132144B1 KR 1020207003791 A KR1020207003791 A KR 1020207003791A KR 20207003791 A KR20207003791 A KR 20207003791A KR 102132144 B1 KR102132144 B1 KR 102132144B1
Authority
KR
South Korea
Prior art keywords
cys
lys
ser
glu
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207003791A
Other languages
English (en)
Korean (ko)
Other versions
KR20200017548A (ko
Inventor
라빈드라 쿠마르
애시아 그린버그
Original Assignee
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악셀레론 파마 인코포레이티드 filed Critical 악셀레론 파마 인코포레이티드
Priority to KR1020207018965A priority Critical patent/KR102305109B1/ko
Publication of KR20200017548A publication Critical patent/KR20200017548A/ko
Application granted granted Critical
Publication of KR102132144B1 publication Critical patent/KR102132144B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207003791A 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 Expired - Fee Related KR102132144B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207018965A KR102305109B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04
US62/007,908 2014-06-04
PCT/US2015/034245 WO2015187977A1 (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000297A Division KR102077286B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207018965A Division KR102305109B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Publications (2)

Publication Number Publication Date
KR20200017548A KR20200017548A (ko) 2020-02-18
KR102132144B1 true KR102132144B1 (ko) 2020-07-09

Family

ID=54767384

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207003791A Expired - Fee Related KR102132144B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020217029755A Ceased KR20210119546A (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020207018965A Expired - Fee Related KR102305109B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020177000297A Expired - Fee Related KR102077286B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217029755A Ceased KR20210119546A (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020207018965A Expired - Fee Related KR102305109B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
KR1020177000297A Expired - Fee Related KR102077286B1 (ko) 2014-06-04 2015-06-04 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Country Status (12)

Country Link
US (2) US10023621B2 (enExample)
EP (2) EP3152237B1 (enExample)
JP (3) JP6568110B2 (enExample)
KR (4) KR102132144B1 (enExample)
CN (2) CN113583104A (enExample)
AU (2) AU2015269333B2 (enExample)
BR (1) BR112016028520A2 (enExample)
CA (1) CA2950754C (enExample)
EA (2) EA202090632A1 (enExample)
MA (2) MA51074A (enExample)
MX (2) MX382908B (enExample)
WO (1) WO2015187977A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
CN102131822A (zh) 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
ES2715710T3 (es) 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EA202090632A1 (ru) 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
EP3274457A4 (en) * 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
SG11201807400TA (en) * 2016-03-04 2018-09-27 Shire Human Genetic Therapies Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
EP3765601A1 (en) * 2018-03-16 2021-01-20 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
CN111902157B (zh) * 2018-03-21 2023-08-04 松阳生技股份有限公司 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
US20210207135A1 (en) * 2018-05-17 2021-07-08 Housey Pharmaceutical Research Laboratories, L.L.C. Inhibition of follistatin
WO2020046466A1 (en) * 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20240101621A1 (en) * 2021-01-26 2024-03-28 Immunis, Inc. Molecular superstructure and methods of use thereof
CN119343367A (zh) 2022-06-15 2025-01-21 Ucb生物制药有限责任公司 卵泡抑素融合蛋白
US20260049114A1 (en) 2022-06-15 2026-02-19 UCB Biopharma SRL Fusion protein for the prevention, treatment or amelioration of kidney diseases
WO2024121351A1 (en) * 2022-12-07 2024-06-13 Lodberg Andreas Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents
WO2025157262A1 (en) * 2024-01-25 2025-07-31 Sichuan Real & Best Biotech Co., Ltd. Nucleic acids encoding follistatin and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012070739A (ja) * 2004-07-23 2012-04-12 Acceleron Pharma Inc ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
JP3670276B2 (ja) * 1991-02-08 2005-07-13 プロゲニクス・ファーマスーティカルズ、インコーポレイテッド ＣＤ４― ガンマ・２キメラ及びＣＤ４ ― ＩｇＧ２・キメラ
CA2144081C (en) 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
MXPA01007366A (es) 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
WO2001009368A1 (en) 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
EP1572909A4 (en) 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
EP1646400B1 (en) 2003-03-21 2010-07-21 Celldex Therapeutics Limited Treatment of allergic diseases using a modulator of the notch signaling pathway
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2005025601A1 (en) 2003-09-15 2005-03-24 Monash University Follistatin isoforms and uses thereof
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
EP2097095B1 (en) 2006-11-29 2016-01-27 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CN102131822A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
DK2318028T3 (da) * 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2844271B1 (en) 2012-05-17 2018-02-28 Paranta Biosciences Limited Use of follistatin or of an activin inhibitor for preventing or treating tissue graft dysfunction
US9943574B2 (en) * 2012-06-27 2018-04-17 Arthrogen B.V. Combination for treating an inflammatory disorder
ES2715710T3 (es) * 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatina en el tratamiento de la distrofía muscular de Duchenne
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
EA202090632A1 (ru) 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EP3274457A4 (en) * 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
CN110914294A (zh) 2017-05-12 2020-03-24 夏尔人类遗传性治疗公司 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012070739A (ja) * 2004-07-23 2012-04-12 Acceleron Pharma Inc ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物

Also Published As

Publication number Publication date
KR20210119546A (ko) 2021-10-05
CN113583104A (zh) 2021-11-02
JP2019203017A (ja) 2019-11-28
KR20170005891A (ko) 2017-01-16
KR102305109B1 (ko) 2021-09-27
KR102077286B1 (ko) 2020-02-13
MX382908B (es) 2025-03-13
CA2950754C (en) 2021-10-26
CA2950754A1 (en) 2015-12-10
US10954279B2 (en) 2021-03-23
CN106795224B (zh) 2021-05-18
JP6568110B2 (ja) 2019-08-28
KR20200084064A (ko) 2020-07-09
JP2021095416A (ja) 2021-06-24
AU2015269333A1 (en) 2016-12-15
MA51074A (fr) 2020-10-14
MX2021006017A (es) 2021-07-06
JP6856716B2 (ja) 2021-04-07
CN106795224A (zh) 2017-05-31
WO2015187977A1 (en) 2015-12-10
MX2016015868A (es) 2017-04-05
EP3152237B1 (en) 2020-04-01
AU2020210315A1 (en) 2020-08-27
EP3721892B1 (en) 2024-05-22
EA035455B1 (ru) 2020-06-18
MA51075A (fr) 2020-10-14
EP3721892A1 (en) 2020-10-14
EA201692529A1 (ru) 2017-05-31
EP3152237A1 (en) 2017-04-12
EA202090632A1 (ru) 2020-07-31
JP2017518303A (ja) 2017-07-06
BR112016028520A2 (pt) 2017-10-24
US10023621B2 (en) 2018-07-17
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
US20160185836A1 (en) 2016-06-30
EP3152237A4 (en) 2017-11-01
AU2015269333B2 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
KR102132144B1 (ko) 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
US20220281951A1 (en) Variants derived from actriib and uses therefor
AU2010322011B2 (en) ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US11497792B2 (en) Methods for treatment of Duchenne muscular dystrophy with follistatin polypeptides
HK1238658B (zh) 用促滤泡素抑制素多肽治疗病症的方法和组合物
HK1236544A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1236544B (en) Methods and compositions for treatment of disorders with follistatin polypeptides

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240703

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240703